Overview
Multimedia
Accommodations
Faculty
Opportunities
Registration

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 7.5 Contact Hours.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation, Ignyta, Lilly, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Pfizer, and Takeda Oncology.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

12th Annual New York Lung Cancers Symposium

12th Annual New York Lung Cancers Symposium


November 11, 2017
New York Marriott Marquis
1535 Broadway

New York, NY 10036
(888) 523-0366


Overview

The 12th Annual New York Lung Cancers Symposium is a 1-day educational and scientific meeting that will provide an update on state-of-the-art management of patients with lung cancer, as well as a focus on future therapies in development.

The past decade in lung cancer research has yielded a wealth of therapeutic options for patients with lung cancer, as well as greater knowledge of the many different subtypes of this disease. In particular, agents targeting oncogenic drivers and immunotherapeutic approaches have transformed the management of patients with lung cancer in recent years. Furthermore, numerous investigational approaches are in late-phase evaluation, with the potential to change standards of care in 2016, and beyond. However, although these developments hold the promise to further improve outcomes for patients with lung cancer, they also raise challenges for busy clinicians to maintain state-of-the-art approaches in their practices.

This year’s program, led by world-class thoracic oncologists, Mark G. Kris, MD, and Roman Perez-Soler, MD, will focus on a number of core areas that are key to optimizing care for patients with lung cancer, including targeted therapy, immunotherapy, adjuvant therapy, combined modality therapy, and approaches for challenging subtypes, such as squamous lung cancer. Participants will have an opportunity to learn from engaging presentations delivered by leading experts, as well as apply their knowledge in case-based panel discussions. This fast-paced, highly practical, and interactive forum will once again provide physicians who treat patients with lung cancer unique access to renowned international experts in the management of these tumors.
 

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation, Ignyta, Lilly, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Pfizer, and Takeda Oncology.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.


Target Audience

This educational activity is directed toward medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists involved in the treatment and management of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer may also participate. 

Learning Objectives

At the conclusion of this activity, participants should be better prepared to:

  • Determine testing strategies to optimize tumor characterization and inform clinical decision making for the management of patients with lung cancers
  • Identify diagnostic and tumor testing results that inform individualized treatment planning and sequencing for patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)
  • Integrate recent clinical trial findings concerning single-agent and combination immunotherapeutic strategies to manage advanced forms of lung cancers
  • Apply personalized approaches to optimize sequencing of oncogenic-driven NSCLC via assessment of mutation subtypes in multiple lines of care
  • Determine frontline and subsequent options in patients without actionable mutations, including the role of chemotherapies and antiangiogenic strategies in these settings
  • Describe methods to proactively plan for and mitigate the impact of treatment-related toxicities in the care of patients with lung cancers


Program Chairs

Mark G. Kris, MD
Attending, Thoracic Oncology Service
William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY




Roman Perez-Soler, MD
Chairman, Department of Oncology
Montefiore Medical Center
Professor of Medicine and Molecular Pharmacology
Deputy Cancer Center Director
Albert Einstein College of Medicine
Bronx, NY





Register

You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information


Registration Information


In case of onsite emergency:

Professional Information


Specialties*

Assumption of Risk and Waiver of Liability Relating to Coronavirus/COVID-19

I understand that the hazards of the novel coronavirus ("COVID-19") and have reviewed the Centers for Disease Control and Prevention ("CDC") current guidelines in regards to COVID-19. I acknowledge that while Physicians' Education Resource, LLC ("PER") ("Company") has put in place preventative measures to reduce the spread of COVID-19, Company cannot guarantee that I or anyone else will not become infected with COVID-19. I attest that if within the fourteen (14) days prior to the event, I am experiencing any symptoms of COVID-19, or I have been in close contact with anyone that has been diagnosed with COVID-19, then I will not attend the Activities. I shall follow any safety, social distancing, masking, and hygiene protocols that have been implemented at the Activities.

I hereby willingly and voluntarily choose to attend this PER event and related activities ("Activity"). I acknowledge and fully assume the risk and hazards of exposure to COVID-19 and that such exposure or infection may result in personal injury, illness, permanent disability, and death to myself, my spouse, children, unborn child, or relatives. I hereby release covenant not to sue, forever discharge, and hold harmless Company and its affiliates from all liability claims and demands of whatever kind of nature, either in law or in equity, which arise or may hereafter arise from participating in the Activities. I assume all risks of losses, damages, or injuries that may be sustained while participating in the Activity. I understand and agree that this release includes any Claims based on the actions, omissions, or negligence of the venue, employees, vendors, agents, and representatives, whether a COVID-19 infection occurs before, during, or after participation in the Activity.

* By checking this box, you have read and understand the above and agree to its terms.

Submit
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
31
Filter By